世界の悪性神経膠腫治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Malignant Glioma Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4458 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、悪性神経膠腫治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（外科療法、放射線療法、化学療法、生物学的療法/標的療法）、用途別市場規模（大人用、子供用）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・悪性神経膠腫治療薬の市場動向 ・企業の競争状況、市場シェア ・悪性神経膠腫治療薬の種類別市場規模と予測2016-2027（外科療法、放射線療法、化学療法、生物学的療法/標的療法） ・悪性神経膠腫治療薬の用途別市場規模と予測2016-2027（大人用、子供用） ・悪性神経膠腫治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・悪性神経膠腫治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・悪性神経膠腫治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・悪性神経膠腫治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・悪性神経膠腫治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Merck、Roche、Arbor Pharmaceuticals、Pfizer、AbbVie、Amgen、Bristol-Myers Squibb、Sun Pharmaceuticals、Teva、Emcure） ・結論

Malignant glioma, a tumor derived from the nerve epithelium, is generally referred to as glioma, accounting for 40-50% of brain tumors, and is the most common intracranial malignant tumor.

Market Analysis and Insights: Global Malignant Glioma Therapeutics Market
The global Malignant Glioma Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Malignant Glioma Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Malignant Glioma Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Malignant Glioma Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Malignant Glioma Therapeutics market.

Global Malignant Glioma Therapeutics Scope and Market Size
Malignant Glioma Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Malignant Glioma Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Chemotherapy
Radiotherapy
Targeted therapy

Segment by Application
Adult
Children

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Merck
Roche
Arbor Pharmaceuticals
Pfizer
AbbVie
Amgen
Bristol-Myers Squibb
Sun Pharmaceuticals
Teva
Emcure

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Malignant Glioma Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Chemotherapy
1.2.3 Radiotherapy
1.2.4 Targeted therapy
1.3 Market by Application
1.3.1 Global Malignant Glioma Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Adult
1.3.3 Children
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Malignant Glioma Therapeutics Market Perspective (2016-2027)
2.2 Malignant Glioma Therapeutics Growth Trends by Regions
2.2.1 Malignant Glioma Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Malignant Glioma Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Malignant Glioma Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Malignant Glioma Therapeutics Industry Dynamic
2.3.1 Malignant Glioma Therapeutics Market Trends
2.3.2 Malignant Glioma Therapeutics Market Drivers
2.3.3 Malignant Glioma Therapeutics Market Challenges
2.3.4 Malignant Glioma Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Malignant Glioma Therapeutics Players by Revenue
3.1.1 Global Top Malignant Glioma Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Malignant Glioma Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Malignant Glioma Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Malignant Glioma Therapeutics Revenue
3.4 Global Malignant Glioma Therapeutics Market Concentration Ratio
3.4.1 Global Malignant Glioma Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Malignant Glioma Therapeutics Revenue in 2020
3.5 Malignant Glioma Therapeutics Key Players Head office and Area Served
3.6 Key Players Malignant Glioma Therapeutics Product Solution and Service
3.7 Date of Enter into Malignant Glioma Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Malignant Glioma Therapeutics Breakdown Data by Type
4.1 Global Malignant Glioma Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Malignant Glioma Therapeutics Forecasted Market Size by Type (2022-2027)

5 Malignant Glioma Therapeutics Breakdown Data by Application
5.1 Global Malignant Glioma Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Malignant Glioma Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Malignant Glioma Therapeutics Market Size (2016-2027)
6.2 North America Malignant Glioma Therapeutics Market Size by Type
6.2.1 North America Malignant Glioma Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Malignant Glioma Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Malignant Glioma Therapeutics Market Size by Type (2016-2027)
6.3 North America Malignant Glioma Therapeutics Market Size by Application
6.3.1 North America Malignant Glioma Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Malignant Glioma Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Malignant Glioma Therapeutics Market Size by Application (2016-2027)
6.4 North America Malignant Glioma Therapeutics Market Size by Country
6.4.1 North America Malignant Glioma Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Malignant Glioma Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Malignant Glioma Therapeutics Market Size (2016-2027)
7.2 Europe Malignant Glioma Therapeutics Market Size by Type
7.2.1 Europe Malignant Glioma Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Malignant Glioma Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Malignant Glioma Therapeutics Market Size by Type (2016-2027)
7.3 Europe Malignant Glioma Therapeutics Market Size by Application
7.3.1 Europe Malignant Glioma Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Malignant Glioma Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Malignant Glioma Therapeutics Market Size by Application (2016-2027)
7.4 Europe Malignant Glioma Therapeutics Market Size by Country
7.4.1 Europe Malignant Glioma Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Malignant Glioma Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Malignant Glioma Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Malignant Glioma Therapeutics Market Size by Type
8.2.1 Asia-Pacific Malignant Glioma Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Malignant Glioma Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Malignant Glioma Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Malignant Glioma Therapeutics Market Size by Application
8.3.1 Asia-Pacific Malignant Glioma Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Malignant Glioma Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Malignant Glioma Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Malignant Glioma Therapeutics Market Size by Region
8.4.1 Asia-Pacific Malignant Glioma Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Malignant Glioma Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Malignant Glioma Therapeutics Market Size (2016-2027)
9.2 Latin America Malignant Glioma Therapeutics Market Size by Type
9.2.1 Latin America Malignant Glioma Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Malignant Glioma Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Malignant Glioma Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Malignant Glioma Therapeutics Market Size by Application
9.3.1 Latin America Malignant Glioma Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Malignant Glioma Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Malignant Glioma Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Malignant Glioma Therapeutics Market Size by Country
9.4.1 Latin America Malignant Glioma Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Malignant Glioma Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Malignant Glioma Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Malignant Glioma Therapeutics Market Size by Type
10.2.1 Middle East & Africa Malignant Glioma Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Malignant Glioma Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Malignant Glioma Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Malignant Glioma Therapeutics Market Size by Application
10.3.1 Middle East & Africa Malignant Glioma Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Malignant Glioma Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Malignant Glioma Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Malignant Glioma Therapeutics Market Size by Country
10.4.1 Middle East & Africa Malignant Glioma Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Malignant Glioma Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Details
11.1.2 Merck Business Overview
11.1.3 Merck Malignant Glioma Therapeutics Introduction
11.1.4 Merck Revenue in Malignant Glioma Therapeutics Business (2016-2021)
11.1.5 Merck Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Malignant Glioma Therapeutics Introduction
11.2.4 Roche Revenue in Malignant Glioma Therapeutics Business (2016-2021)
11.2.5 Roche Recent Development
11.3 Arbor Pharmaceuticals
11.3.1 Arbor Pharmaceuticals Company Details
11.3.2 Arbor Pharmaceuticals Business Overview
11.3.3 Arbor Pharmaceuticals Malignant Glioma Therapeutics Introduction
11.3.4 Arbor Pharmaceuticals Revenue in Malignant Glioma Therapeutics Business (2016-2021)
11.3.5 Arbor Pharmaceuticals Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Malignant Glioma Therapeutics Introduction
11.4.4 Pfizer Revenue in Malignant Glioma Therapeutics Business (2016-2021)
11.4.5 Pfizer Recent Development
11.5 AbbVie
11.5.1 AbbVie Company Details
11.5.2 AbbVie Business Overview
11.5.3 AbbVie Malignant Glioma Therapeutics Introduction
11.5.4 AbbVie Revenue in Malignant Glioma Therapeutics Business (2016-2021)
11.5.5 AbbVie Recent Development
11.6 Amgen
11.6.1 Amgen Company Details
11.6.2 Amgen Business Overview
11.6.3 Amgen Malignant Glioma Therapeutics Introduction
11.6.4 Amgen Revenue in Malignant Glioma Therapeutics Business (2016-2021)
11.6.5 Amgen Recent Development
11.7 Bristol-Myers Squibb
11.7.1 Bristol-Myers Squibb Company Details
11.7.2 Bristol-Myers Squibb Business Overview
11.7.3 Bristol-Myers Squibb Malignant Glioma Therapeutics Introduction
11.7.4 Bristol-Myers Squibb Revenue in Malignant Glioma Therapeutics Business (2016-2021)
11.7.5 Bristol-Myers Squibb Recent Development
11.8 Sun Pharmaceuticals
11.8.1 Sun Pharmaceuticals Company Details
11.8.2 Sun Pharmaceuticals Business Overview
11.8.3 Sun Pharmaceuticals Malignant Glioma Therapeutics Introduction
11.8.4 Sun Pharmaceuticals Revenue in Malignant Glioma Therapeutics Business (2016-2021)
11.8.5 Sun Pharmaceuticals Recent Development
11.9 Teva
11.9.1 Teva Company Details
11.9.2 Teva Business Overview
11.9.3 Teva Malignant Glioma Therapeutics Introduction
11.9.4 Teva Revenue in Malignant Glioma Therapeutics Business (2016-2021)
11.9.5 Teva Recent Development
11.10 Emcure
11.10.1 Emcure Company Details
11.10.2 Emcure Business Overview
11.10.3 Emcure Malignant Glioma Therapeutics Introduction
11.10.4 Emcure Revenue in Malignant Glioma Therapeutics Business (2016-2021)
11.10.5 Emcure Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Malignant Glioma Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Chemotherapy
Table 3. Key Players of Radiotherapy
Table 4. Key Players of Targeted therapy
Table 5. Global Malignant Glioma Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Malignant Glioma Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Malignant Glioma Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Malignant Glioma Therapeutics Market Share by Regions (2016-2021)
Table 9. Global Malignant Glioma Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Malignant Glioma Therapeutics Market Share by Regions (2022-2027)
Table 11. Malignant Glioma Therapeutics Market Trends
Table 12. Malignant Glioma Therapeutics Market Drivers
Table 13. Malignant Glioma Therapeutics Market Challenges
Table 14. Malignant Glioma Therapeutics Market Restraints
Table 15. Global Malignant Glioma Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Malignant Glioma Therapeutics Market Share by Players (2016-2021)
Table 17. Global Top Malignant Glioma Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Glioma Therapeutics as of 2020)
Table 18. Ranking of Global Top Malignant Glioma Therapeutics Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Malignant Glioma Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Malignant Glioma Therapeutics Product Solution and Service
Table 22. Date of Enter into Malignant Glioma Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Malignant Glioma Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Malignant Glioma Therapeutics Revenue Market Share by Type (2016-2021)
Table 26. Global Malignant Glioma Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Malignant Glioma Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Malignant Glioma Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Malignant Glioma Therapeutics Revenue Market Share by Application (2016-2021)
Table 30. Global Malignant Glioma Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Malignant Glioma Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Malignant Glioma Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Malignant Glioma Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Malignant Glioma Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Malignant Glioma Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Malignant Glioma Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Malignant Glioma Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Malignant Glioma Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Malignant Glioma Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Malignant Glioma Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Malignant Glioma Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Malignant Glioma Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Malignant Glioma Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Malignant Glioma Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Malignant Glioma Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Malignant Glioma Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Malignant Glioma Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Malignant Glioma Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Malignant Glioma Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Malignant Glioma Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Malignant Glioma Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Malignant Glioma Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Malignant Glioma Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Malignant Glioma Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Malignant Glioma Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Malignant Glioma Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Malignant Glioma Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Malignant Glioma Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Malignant Glioma Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Malignant Glioma Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Malignant Glioma Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 62. Merck Company Details
Table 63. Merck Business Overview
Table 64. Merck Malignant Glioma Therapeutics Product
Table 65. Merck Revenue in Malignant Glioma Therapeutics Business (2016-2021) & (US$ Million)
Table 66. Merck Recent Development
Table 67. Roche Company Details
Table 68. Roche Business Overview
Table 69. Roche Malignant Glioma Therapeutics Product
Table 70. Roche Revenue in Malignant Glioma Therapeutics Business (2016-2021) & (US$ Million)
Table 71. Roche Recent Development
Table 72. Arbor Pharmaceuticals Company Details
Table 73. Arbor Pharmaceuticals Business Overview
Table 74. Arbor Pharmaceuticals Malignant Glioma Therapeutics Product
Table 75. Arbor Pharmaceuticals Revenue in Malignant Glioma Therapeutics Business (2016-2021) & (US$ Million)
Table 76. Arbor Pharmaceuticals Recent Development
Table 77. Pfizer Company Details
Table 78. Pfizer Business Overview
Table 79. Pfizer Malignant Glioma Therapeutics Product
Table 80. Pfizer Revenue in Malignant Glioma Therapeutics Business (2016-2021) & (US$ Million)
Table 81. Pfizer Recent Development
Table 82. AbbVie Company Details
Table 83. AbbVie Business Overview
Table 84. AbbVie Malignant Glioma Therapeutics Product
Table 85. AbbVie Revenue in Malignant Glioma Therapeutics Business (2016-2021) & (US$ Million)
Table 86. AbbVie Recent Development
Table 87. Amgen Company Details
Table 88. Amgen Business Overview
Table 89. Amgen Malignant Glioma Therapeutics Product
Table 90. Amgen Revenue in Malignant Glioma Therapeutics Business (2016-2021) & (US$ Million)
Table 91. Amgen Recent Development
Table 92. Bristol-Myers Squibb Company Details
Table 93. Bristol-Myers Squibb Business Overview
Table 94. Bristol-Myers Squibb Malignant Glioma Therapeutics Product
Table 95. Bristol-Myers Squibb Revenue in Malignant Glioma Therapeutics Business (2016-2021) & (US$ Million)
Table 96. Bristol-Myers Squibb Recent Development
Table 97. Sun Pharmaceuticals Company Details
Table 98. Sun Pharmaceuticals Business Overview
Table 99. Sun Pharmaceuticals Revenue in Malignant Glioma Therapeutics Business (2016-2021) & (US$ Million)
Table 100. Sun Pharmaceuticals Recent Development
Table 101. Teva Company Details
Table 102. Teva Business Overview
Table 103. Teva Malignant Glioma Therapeutics Product
Table 104. Teva Revenue in Malignant Glioma Therapeutics Business (2016-2021) & (US$ Million)
Table 105. Teva Recent Development
Table 106. Emcure Company Details
Table 107. Emcure Business Overview
Table 108. Emcure Malignant Glioma Therapeutics Product
Table 109. Emcure Revenue in Malignant Glioma Therapeutics Business (2016-2021) & (US$ Million)
Table 110. Emcure Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Malignant Glioma Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Chemotherapy Features
Figure 3. Radiotherapy Features
Figure 4. Targeted therapy Features
Figure 5. Global Malignant Glioma Therapeutics Market Share by Application: 2020 VS 2027
Figure 6. Adult Case Studies
Figure 7. Children Case Studies
Figure 8. Malignant Glioma Therapeutics Report Years Considered
Figure 9. Global Malignant Glioma Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Malignant Glioma Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Malignant Glioma Therapeutics Market Share by Regions: 2020 VS 2027
Figure 12. Global Malignant Glioma Therapeutics Market Share by Regions (2022-2027)
Figure 13. Global Malignant Glioma Therapeutics Market Share by Players in 2020
Figure 14. Global Top Malignant Glioma Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Glioma Therapeutics as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Malignant Glioma Therapeutics Revenue in 2020
Figure 16. Global Malignant Glioma Therapeutics Revenue Market Share by Type (2016-2021)
Figure 17. Global Malignant Glioma Therapeutics Revenue Market Share by Type (2022-2027)
Figure 18. North America Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Malignant Glioma Therapeutics Market Share by Type (2016-2027)
Figure 20. North America Malignant Glioma Therapeutics Market Share by Application (2016-2027)
Figure 21. North America Malignant Glioma Therapeutics Market Share by Country (2016-2027)
Figure 22. United States Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Malignant Glioma Therapeutics Market Share by Type (2016-2027)
Figure 26. Europe Malignant Glioma Therapeutics Market Share by Application (2016-2027)
Figure 27. Europe Malignant Glioma Therapeutics Market Share by Country (2016-2027)
Figure 28. Germany Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Malignant Glioma Therapeutics Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Malignant Glioma Therapeutics Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Malignant Glioma Therapeutics Market Share by Region (2016-2027)
Figure 38. China Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Malignant Glioma Therapeutics Market Share by Type (2016-2027)
Figure 46. Latin America Malignant Glioma Therapeutics Market Share by Application (2016-2027)
Figure 47. Latin America Malignant Glioma Therapeutics Market Share by Country (2016-2027)
Figure 48. Mexico Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Malignant Glioma Therapeutics Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Malignant Glioma Therapeutics Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Malignant Glioma Therapeutics Market Share by Country (2016-2027)
Figure 54. Turkey Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Malignant Glioma Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Merck Revenue Growth Rate in Malignant Glioma Therapeutics Business (2016-2021)
Figure 58. Roche Revenue Growth Rate in Malignant Glioma Therapeutics Business (2016-2021)
Figure 59. Arbor Pharmaceuticals Revenue Growth Rate in Malignant Glioma Therapeutics Business (2016-2021)
Figure 60. Pfizer Revenue Growth Rate in Malignant Glioma Therapeutics Business (2016-2021)
Figure 61. AbbVie Revenue Growth Rate in Malignant Glioma Therapeutics Business (2016-2021)
Figure 62. Amgen Revenue Growth Rate in Malignant Glioma Therapeutics Business (2016-2021)
Figure 63. Bristol-Myers Squibb Revenue Growth Rate in Malignant Glioma Therapeutics Business (2016-2021)
Figure 64. Sun Pharmaceuticals Revenue Growth Rate in Malignant Glioma Therapeutics Business (2016-2021)
Figure 65. Teva Revenue Growth Rate in Malignant Glioma Therapeutics Business (2016-2021)
Figure 66. Emcure Revenue Growth Rate in Malignant Glioma Therapeutics Business (2016-2021)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed

---